Show simple item record

dc.contributor.authorKaye, SBen_US
dc.date.accessioned2018-06-25T14:37:43Z
dc.date.issued2005-05en_US
dc.identifier.citationInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2005, 15 Suppl 1 pp. 31 - 35en_US
dc.identifier.issn1048-891Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1911
dc.identifier.eissn1525-1438en_US
dc.identifier.doi10.1111/j.1525-1438.2005.15354.xen_US
dc.description.abstractSubstantial progress has been made since the early 1990s regarding the treatment of patients with ovarian cancer. Those patients relapsing more than 6 months after platinum-based chemotherapy may benefit from repeat chemotherapy that includes carboplatin. When the treatment-free interval is >12 months, carboplatin combined with paclitaxel (or possibly another agent) is likely to provide a survival advantage compared with carboplatin monotherapy. Evidence to support this comes from the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial, a prospective randomized trial of 802 patients designed to assess the potential benefit of combining carboplatin with paclitaxel. One arm of the trial contained patients randomized to conventional platinum-based therapy, while those randomized to the second arm received a paclitaxel-platinum combination. There was a 7% increase in survival for paclitaxel-based treatment (2-year increase from 50% to 57%; P = 0.02) and a 10% increase in progression-free survival (1-year increase from 40% to 50% in favor of paclitaxel-based treatment; P = 0.0004). The major observed differences between the treatment arms in terms of toxicity were significant alopecia (25% versus 86% in arms 1 and 2, respectively), neurotoxicity (1% versus 20%), and hematologic toxicity (46% versus 29%). When the treatment-free interval was between 6 and 12 months, the extent of the benefit was less clear and further trials are certainly warranted.en_US
dc.formatPrinten_US
dc.format.extent31 - 35en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectHumansen_US
dc.subjectOvarian Neoplasmsen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectCisplatinen_US
dc.subjectPaclitaxelen_US
dc.subjectCarboplatinen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectSurvival Analysisen_US
dc.subjectTime Factorsen_US
dc.subjectAgeden_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.titleManagement of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/j.1525-1438.2005.15354.xen_US
rioxxterms.licenseref.startdate2005-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Societyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.publication-statusPublisheden_US
pubs.volume15 Suppl 1en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine Drug Development Unit (Kaye)en_US
dc.contributor.icrauthorKaye, Stanley Bernarden_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record